Andremacon opens a new operational innovation headquarters including research facilities and technological platforms in Milan in the UNIMI Foundation hub, founded by the University of Milan, together with the Cariplo Foundation, Intesa Sanpaolo and the Milan Chamber of Commerce.

Located in the south of Milan, a stone's throw from the Prada Foundation, the IFOM research center and the Calabiana Talent Garden, the complex welcomes start-ups, companies and laboratories with the aim of facilitating the transfer of knowledge and technology from the academy to the market and for the creation of technological and innovative initiatives.

Andremacon' laboratories are a state-of-the-art facility equipped with the most innovative instruments for advanced cellular and molecular research. 

Our research facilities are equipped for:

  • cell culture with the latest technologies for growing and maintaining several cell lines, the lab supports research into cellular behavior under both normal and pathological conditions;
  • biomarker Identification; the laboratory is capable of identifying and analyzing biomarkers, key molecular indicators of disease, which are crucial for the development of targeted therapies and diagnostics;
  • isolation of extracellular vesicles: with advanced tools such as ultracentrifuge, for isolating extracellular vesicles and exosomes, to study the critical mediators of intercellular communication, with potential implications for cancer, neurodegeneration, and other diseases;
  • cancer stem cell platforms with the creation of complex cellular platforms made by the organoid culture of cancer stem cells, endothelial cells and immune cells to model tissue microenvironments, essential for testing drug efficacy and understanding cellular interactions in a controlled, reproducible scenario;
  • microfluidic dynamic platform: microfluidic technology allows the study of fluid dynamics at a microscopic level, providing insights into how cells and molecules behave in physiological and pathological conditions, such as in tumor microenvironments or during inflammation.

Together, these capabilities allow Andremacon to conduct the newest and most advanced research aimed at improving scientific knowledge and driving therapeutic innovation.